17-247 - IV Iron Therapy vs Placebo in the Treatment of Participants in Heart Failure with Iron DeficiencyStatus: open
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency
Treatment for Heart Failure with Iron deficiency
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at firstname.lastname@example.org.
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of participants in heart failure with iron deficiency and with a reduced ejection fraction.
SponsorsThis trial is sponsored by Luitpold Pharmaceuticals.
Providers Associated With This Trial
- Christopher M. Malozzi, D.O.CardiologistAssociate Professor of Internal Medicine
- Bassam A. Omar, M.D., Ph.D., F.A.C.C.CardiologistFellowship Director of Cardiovascular Diseases; Professor of Internal Medicine
- Michael V. Cohen, M.D.CardiologistProfessor of Physiology and Cell Biology
- Ghulam Mustafa Awan, M.D.Interventional CardiologistDirector of Interventional Cardiology and Endovascular Interventions; Associate Professor of Internal Medicine